Filtered By:
Source: The Lancet
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 18 results found since Jan 2013.
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Publication date: Available online 14 March 2015 Source:The Lancet Author(s): Freek W A Verheugt , Christopher B Granger In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that dire...
Source: The Lancet - March 14, 2015 Category: Journals (General) Source Type: research
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Publication date: Available online 8 August 2016 Source:The Lancet Author(s): Jeff S Healey, Jonas Oldgren, Michael Ezekowitz, Jun Zhu, Prem Pais, Jia Wang, Patrick Commerford, Petr Jansky, Alvaro Avezum, Alben Sigamani, Albertino Demasceno, Paul Reilly, Alex Grinvalds, Juliet Nakamya, Akinyemi Aje, Wael Almahmeed, Andrew Moriarty, Lars Wallentin, Salim Yusuf, Stuart J Connolly Background Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in individuals outside North America or Europe, especially in primary care settings. Methods We did a coh...
Source: The Lancet - August 8, 2016 Category: Journals (General) Source Type: research
Stroke prevention in atrial fibrillation
Publication date: 20–26 August 2016 Source:The Lancet, Volume 388, Issue 10046 Author(s): Ben Freedman, Tatjana S Potpara, Gregory Y H Lip Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fibrillation monitoring. Data from stroke registries show that both unknown and untreated or under treated atrial fibrillation is responsible for most of these strokes, which are often fatal or debilitating. Most could be prevented if efforts were directed towards detection of atrial fibrillation before stroke occurs, through screening or case finding, and treatment of all patients wi...
Source: The Lancet - August 18, 2016 Category: Journals (General) Source Type: research
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Publication date: Available online 6 March 2015 Source:The Lancet Author(s): Jeffrey B Washam , Susanna R Stevens , Yuliya Lokhnygina , Jonathan L Halperin , Günter Breithardt , Daniel E Singer , Kenneth W Mahaffey , Graeme J Hankey , Scott D Berkowitz , Christopher C Nessel , Keith A A Fox , Robert M Califf , Jonathan P Piccini , Manesh R Patel Background Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Com...
Source: The Lancet - March 6, 2015 Category: Journals (General) Source Type: research
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Publication date: Available online 11 March 2015 Source:The Lancet Author(s): Christian T Ruff , Robert P Giugliano , Eugene Braunwald , David A Morrow , Sabina A Murphy , Julia F Kuder , Naveen Deenadayalu , Petr Jarolim , Joshua Betcher , Minggao Shi , Karen Brown , Indravadan Patel , Michele Mercuri , Elliott M Antman Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or ...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Publication date: 11–17 August 2018Source: The Lancet, Volume 392, Issue 10146Author(s): Araz Rawshani, Naveed Sattar, Stefan Franzén, Aidin Rawshani, Andrew T Hattersley, Ann-Marie Svensson, Björn Eliasson, Soffia GudbjörnsdottirSummaryBackgroundPeople with type 1 diabetes are at elevated risk of mortality and cardiovascular disease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk.MethodsWe did a nationwide, register-based cohort study of individuals with type 1 diabetes...
Source: The Lancet - August 10, 2018 Category: General Medicine Source Type: research
The future of atrial fibrillation management: integrated care and stratified therapy
Publication date: Available online 28 April 2017 Source:The Lancet Author(s): Paulus Kirchhof Atrial fibrillation is one of the major cardiovascular health problems: it is a common, chronic condition, affecting 2–3% of the population in Europe and the USA and requiring 1–3% of health-care expenditure as a result of stroke, sudden death, heart failure, unplanned hospital admissions, and other complications. Early diagnosis of atrial fibrillation, ideally before the first complication occurs, remains a challenge, as shown by patients who are only diagnosed with the condition when admitted to hospital for acute cardiac d...
Source: The Lancet - April 29, 2017 Category: Journals (General) Source Type: research
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
This study was a two-arm, prospective, international, cluster-randomised, controlled trial. Patients were included who had atrial fibrillation and an indication for oral anticoagulation. Clusters were randomised (1:1) to receive a quality improvement educational intervention (intervention group) or usual care (control group). Randomisation was carried out centrally, using the eClinicalOS electronic data capture system. The intervention involved education of providers and patients, with regular monitoring and feedback. The primary outcome was the change in the proportion of patients treated with oral anticoagulants from bas...
Source: The Lancet - August 29, 2017 Category: General Medicine Source Type: research
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Publication date: Available online 7 May 2015 Source:The Lancet Author(s): Renate B Schnabel , Xiaoyan Yin , Philimon Gona , Martin G Larson , Alexa S Beiser , David D McManus , Christopher Newton-Cheh , Steven A Lubitz , Jared W Magnani , Patrick T Ellinor , Sudha Seshadri , Philip A Wolf , Ramachandran S Vasan , Emelia J Benjamin , Daniel Levy Background Comprehensive long-term data on atrial fibrillation trends in men and women are scant. We aimed to provide such data through analysis of the Framingham cohort over 50 years. Methods We investigated trends in incidence, prevalence, and risk factors for atrial fibrillat...
Source: The Lancet - May 9, 2015 Category: Journals (General) Source Type: research
Edoxaban versus enoxaparin –warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
Publication date: Available online 30 August 2016 Source:The Lancet Author(s): Andreas Goette, Jose L Merino, Michael D Ezekowitz, Dmitry Zamoryakhin, Michael Melino, James Jin, Michele F Mercuri, Michael A Grosso, Victor Fernandez, Naab Al-Saady, Natalya Pelekh, Bela Merkely, Sergey Zenin, Mykola Kushnir, Jindrich Spinar, Valeriy Batushkin, Joris R de Groot, Gregory Y H Lip Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled enoxaparin–warfarin therapy. Few safety d...
Source: The Lancet - August 30, 2016 Category: Journals (General) Source Type: research
Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial
Publication date: Available online 23 July 2015 Source:The Lancet Author(s): Laurent Macle, Paul Khairy, Rukshen Weerasooriya, Paul Novak, Atul Verma, Stephan Willems, Thomas Arentz, Isabel Deisenhofer, George Veenhuyzen, Christophe Scavée, Pierre Jaïs, Helmut Puererfellner, Sylvie Levesque, Jason G Andrade, Lena Rivard, Peter G Guerra, Marc Dubuc, Bernard Thibault, Mario Talajic, Denis Roy, Stanley Nattel Background Catheter ablation is increasingly used to manage atrial fibrillation, but arrhythmia recurrences are common. Adenosine might identify pulmonary veins at risk of reconnection by unmaski...
Source: The Lancet - July 29, 2015 Category: Journals (General) Source Type: research
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Publication date: Available online 4 April 2016 Source:The Lancet Author(s): Ziad Hijazi, Jonas Oldgren, Johan Lindbäck, John H Alexander, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Claes Held, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn, Salim Yusuf, Christopher B Granger, Lars Wallentin Background The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major bleeding. We aimed to develop and validate a new biomarker-based risk score to improve the prognostication of major bleeding in patients with atrial fib...
Source: The Lancet - April 4, 2016 Category: Journals (General) Source Type: research
Stroke and mortality after atrial fibrillation —a global struggle
Publication date: Available online 8 August 2016 Source:The Lancet Author(s): Torben Bjerregaard Larsen, Peter Brønnum Nielsen
Source: The Lancet - August 8, 2016 Category: Journals (General) Source Type: research
Atrial fibrillation and stroke: unrecognised and undertreated
Publication date: 20–26 August 2016 Source:The Lancet, Volume 388, Issue 10046 Author(s): The Lancet
Source: The Lancet - August 18, 2016 Category: Journals (General) Source Type: research
Risk of mortality and stroke after atrial fibrillation
Publication date: 4–10 March 2017 Source:The Lancet, Volume 389, Issue 10072 Author(s): Constantinos Mihas, Anargiros Mariolis, Konstantinos P Letsas, Maria Kantzanou
Source: The Lancet - March 2, 2017 Category: Journals (General) Source Type: research
